Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News CNS Pharmaceuticals Inc. CNSP

CNS Pharmaceuticals Inc is a preclinical stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma.


Recent & Breaking News (NDAQ:CNSP)

CNS Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

PR Newswire 21 hours ago

CNS Pharmaceuticals Urges Shareholders to Vote in Favor of Proxy Proposals for the Upcoming Annual Meeting of Shareholders on July 27, 2022

PR Newswire July 25, 2022

CNS Pharmaceuticals Receives Approval from U.S. FDA for Protocol Amendment to Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

PR Newswire June 23, 2022

CNS Pharmaceuticals Announces Presentation of Ongoing Potentially Pivotal Berubicin Clinical Trial Design at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

PR Newswire June 8, 2022

CNS Pharmaceuticals Announces Presentation at the H.C. Wainwright Global Investment Conference

PR Newswire May 24, 2022

CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

PR Newswire May 18, 2022

CNS Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

PR Newswire May 16, 2022

CNS Pharmaceuticals Receives Approval from Ethics Committee and Competent Authority in Spain for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

PR Newswire April 28, 2022

JTC Team Announces Continuation of its Virtual Investor Spotlight Series with NASDAQ: AEZS, NASDAQ: CNSP, and NASDAQ: AREC

Accesswire April 13, 2022

CNS Pharmaceuticals to Participate in the Virtual Investor Glioblastoma Multiforme (GBM) Spotlight Event

PR Newswire April 12, 2022

CNS Pharmaceuticals Receives Approval from France Ethics Committee and Competent Authority for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

PR Newswire April 6, 2022

CNS Pharmaceuticals Receives Approval from Competent Authority of Switzerland for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

PR Newswire April 5, 2022

CNS Pharmaceuticals to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest

PR Newswire March 23, 2022

CNS Pharmaceuticals Reiterates Operational Progress and Addresses Recent Share Price Activity in Video to Shareholders

PR Newswire March 9, 2022

CNS Pharmaceuticals Reports Full Year 2021 Financial Results and Provides Corporate Update

PR Newswire March 3, 2022

WPD Pharmaceuticals Secures Berubicin Sub-License Rights in Perpetuity

GlobeNewswire February 1, 2022

CNS Pharmaceuticals to Present at the Virtual Investor 2022 Top Picks Conference

PR Newswire January 20, 2022

JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th

Accesswire January 12, 2022

CNS Pharmaceuticals Announces Closing of $11.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

PR Newswire January 10, 2022

CNS Pharmaceuticals to Present at the H.C. Wainwright BioConnect Conference

PR Newswire January 7, 2022